GPC3-Targeted Antibody-Drug Conjugates With Camptothecin Payloads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates targeting glypican-3 (GPC3) have shown limited efficacy in clinical trials, with some demonstrating a good safety profile but no therapeutic effect, while others have not been clinically evaluated.
Innovation Solution
Development of antibody-drug conjugates comprising a specific anti-GPC3 antibody construct conjugated to a camptothecin analogue via a linker, with defined CDR sequences for targeted binding to GPC3 and minimal cross-reactivity with other glypican proteins, and optimized for cancer cell proliferation inhibition and killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibody-drug conjugates targeting GPC3 are used, then safety profile is improved, but therapeutic efficacy is worsened
Solution Approach 1:
The patent changes the drug payload parameters by using camptothecin analogues (e.g., SN-38, irinotecan, topotecan) instead of conventional cytotoxic agents, and optimizes the drug-to-antibody ratio (DAR 1-4) to achieve both safety and efficacy. The linker chemistry parameters are also optimized using pH-sensitive linkers that remain stable in circulation but release payload in the acidic tumor microenvironment.
Solution Approach 2:
The patent creates a composite antibody-drug conjugate system combining specific anti-GPC3 antibody constructs (e.g., 4A6, YP7, M3-H1L1) with camptothecin analogues through optimized linkers. This composite structure leverages the targeting capability of the antibody and the potent cytotoxicity of the camptothecin analogue to achieve both safety and therapeutic efficacy.
2Ease of manufacture
If antibody-drug conjugates with conventional payloads are used, then manufacturing simplicity is improved, but cytotoxicity and tumor remission are worsened
Solution Approach 1:
The patent changes the payload parameters to camptothecin analogues which have established manufacturing protocols, and optimizes conjugation parameters (DAR 1-4, linker type) to maintain manufacturability while achieving potent cytotoxicity and tumor remission in preclinical models.
3Device complexity
If existing ADC formulations are used, then pharmacokinetic simplicity is improved, but efficacy in cancer cell models is worsened
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by selecting appropriate antibody isotypes (IgG1, IgG2, IgG3, IgG4) with different half-lives and FcRn binding affiniciencies, and adjusts the drug-to-antibody ratio (DAR 1-4) to achieve desired pharmacokinetic profiles while maintaining high efficacy in cancer cell models through the camptothecin analogue payload.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed ADCs exhibit potent cytotoxicity in cancer cell models and xenograft models, demonstrating significant tumor remission and bystander effect, with improved pharmacokinetic profiles and efficacy in preclinical studies.
Implementation Method 1
Camptothecin analogues have been developed as payloads for ADCs... Two such ADCs have been approved for treatment of cancer... Trastuzumab deruxtecan (EnhertuTM) in which the camptothecin analogue, deruxtecan (Dxd), is conjugated to the anti-HER2 antibody
Implementation Method 2
Numerous antibodies binding to human GPC3 have been described... International Patent Publication No. WO2021/226321 (Phanes Therapeutics) describes several anti-GPC3 paratopes that specifically bind to human GPC3
Data Source
AI summary
Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds human glypican 3 (GPC3) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.